P1446: PHASE I STUDY DATA UPDATE OF PHE885, A FULLY HUMAN BCMA-DIRECTED CAR-T CELL THERAPY MANUFACTURED USING THE T-CHARGETM PLATFORM FOR PATIENTS WITH RELAPSED/REFRACTORY (R/R) MULTIPLE MYELOMA (MM). (23rd June 2022)

• Record Type: Journal Article
• Authors: Sperling, A. S.; Nikiforow, S.; Derman, B.; Nadeem, O.; Mo, C.; Laubach, J.; Anderson, K.; Alonso, A.; Im, S.-Y.; Ikwgawa, S.; Prabhala, R.; Hernandez Rodriduez, D.; Daley, H.; Shaw, K. L.; Arihara, Y.; Ansari, S.; Quinn, D. S.; Pearson, D.; Hack, A.; Treanor, L.; Bu, D.; Mataraza, J.; Rispoli, L.; Credi, M.; Ritz, J.; Jakubowiak, A.; De Vita, S.; Munshi, N.
• Is Part Of: HemaSphere. Volume 6(2022)Supplement 3
• Page Start: 1329
• Page End: 1330
• Publication Date: 2022-06-23
• Subjects: Hematology -- Periodicals; 616.15005
• DOI: 10.1097/01.HS9.0000848640.53562.8f
• Languages: English
• ISSNs: 2572-9241